The World Health Organization issued a medical product alert on June 16, 2026, warning healthcare regulators and distribution networks in multiple countries about falsified versions of ruxolitinib, a medication used to treat certain forms of leukemia and myelofibrosis sold under the brand name Jakavi.
WHO’s alert system identified falsified packages in circulation in some markets, with suspect products believed to contain incorrect active ingredients, wrong dosages or no therapeutic substance. Patients relying on ruxolitinib for serious blood cancers face direct health risk if unknowingly supplied with counterfeit products that do not deliver the intended therapeutic effect.
The agency advised national regulatory authorities to investigate supply chains, pharmacy dispensing networks and distribution channels to identify and remove suspect products. Healthcare providers were instructed to inspect packaging for authentication features and report suspicious samples through established national pharmacovigilance reporting channels.
Falsified cancer drugs carry particular danger because patients may forego alternative treatment options while believing they are receiving effective therapy. WHO stated it was coordinating with Novartis, Jakavi’s originator manufacturer, to support authentication and market surveillance efforts in affected countries.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.who.int/news-room